Assessment of thromboembolic risk and preventive strategies in major orthopaedic surgery
DOI:
https://doi.org/10.56294/ri202618Keywords:
ETV, arthroplasty, aspirin, heparin, prophylaxisAbstract
Introduction: Venous thromboembolic disease (VTD), comprising deep vein thrombosis (DVT) and pulmonary embolism (PE), was one of the main causes of preventable mortality in hospitalized patients. Its incidence increased significantly in those who underwent hip (THA) and knee (TKA) arthroplasty, which led to the development of effective prevention strategies.
Development: Risk factors associated with both the patient and the surgical procedure were identified. The Caprini scale was used to stratify them, including in orthopedic patients. In terms of pharmacological prophylaxis, anticoagulants such as low molecular weight heparins (LMWH), direct oral anticoagulants (DOAC) and aspirin (ASA) were compared. Different studies showed that ASA was similarly effective to LMWH in low-risk patients, with advantages such as lower cost and better tolerance. However, DOACs offered a slight superiority in efficacy, although with a higher risk of bleeding. Current recommendations favored a combination of pharmacological and mechanical measures such as early ambulation and the use of compression stockings.
Conclusion: The prevention of VTE in major orthopedic surgery required an individualized and evidence-based approach. Aspirin emerged as a valid alternative in certain cases, without completely replacing other anticoagulants in high-risk patients. Further research was considered essential, especially in local contexts such as Argentina, to adapt strategies according to the needs of the health system.
References
1. Vázquez FJ, Grande Ratti MF. Incidencia de la enfermedad tromboembólica venosa adquirida en la internacionalización [Internet]. Org.ar; 2018 [citado 16 jul 2024]. Disponible en: https://www1.hospitalitaliano.org.ar/multimedia/archivos/noticias_attachs/47/documentos/76938_163-164%20HI4-10-Vazquez-A.pdf
2. Gutiérrez Guisado J. Profilaxis tromboembólica en cirugía ortopédica y traumatología. Rev Clin Esp [Internet]. 2020;220:25–32. Disponible en: http://dx.doi.org/10.1016/j.rce.2020.04.016
3. Gutiérrez M, Leache L, Saiz LC, Erviti J. Profilaxis antitrombótica en cirugía ortopédica y traumatología [Internet]. Navarra.es; 2021 [citado 16 jul 2024]. Disponible en: https://www.navarra.es/NR/rdonlyres/B392D594-8010-4121-8F7B-7BA4BE674260/474710/Profilaxisantitrombotica_def.pdf
4. Rodríguez FC. Módulo 5: Tromboprofilaxis en traumatología y cirugía deportiva [Internet]. Campus.sanofi; 2023. Disponible en: https://pro.campus.sanofi/es/osteoartritis/recursos/actualizacion-recomendaciones-tromboprofilaxis-traumatologia-cirugia-deportiva
5. Núñez JH, Moreira F, Escudero-Cisneros B, Martínez-Peña J, Bosch-García D, Anglès F, et al. Riesgo de tromboembolismo venoso entre aspirina y HBPM tras artroplastia total de cadera o rodilla: revisión sistemática y metaanálisis. Rev Esp Cir Ortop Traumatol [Internet]. 2024;68(4):409–21. Disponible en: http://dx.doi.org/10.1016/j.recot.2023.07.003
6. Castel Oñate A. Cambio de paradigma en la tromboprofilaxis en COT [Internet]. Secot.es; 2023 [citado 16 jul 2024]. Disponible en: https://www.secot.es/media/docs/guiatromboprofilaxis/Gu%C3%ADa%20Tromboprofilaxis.pdf
7. Migliorini F, Maffulli N, Velaj E, Bell A, Kämmer D, Hildebrand F, et al. Antithrombotic prophylaxis following total hip arthroplasty: Bayesian network meta-analysis. J Orthop Traumatol [Internet]. 2024;25(1). Disponible en: http://dx.doi.org/10.1186/s10195-023-00742-2
8. Sidhu VS, Kelly TL, Pratt N, Graves SE, Buchbinder R, et al. Effect of aspirin vs enoxaparin in arthroplasty: CRISTAL trial. JAMA [Internet]. 2022;328(8):719. Disponible en: http://dx.doi.org/10.1001/jama.2022.13416
9. Marrannes S, Victor K, Arnout N, De Backer T, Victor J, Tampere T. VTE prevention with aspirin after knee surgery: review. EFORT Open Rev [Internet]. 2021;6(10):892–904. Disponible en: http://dx.doi.org/10.1302/2058-5241.6.200120
10. Farey JE, An VVG, Sidhu V, Karunaratne S, Harris IA. Aspirin vs enoxaparin for VTE prophylaxis: meta-analysis. Orthop Traumatol Surg Res [Internet]. 2021;107(1):102606. Disponible en: http://dx.doi.org/10.1016/j.otsr.2020.04.002
11. Ma JK, Chen YQ, Zhang LY. DOACs vs aspirin for thromboembolism after arthroplasty: review [Internet]. Europeanreview.org [citado 16 jul 2024]. Disponible en: https://www.europeanreview.org/wp/wp-content/uploads/6245-6259.pdf
12. Singh G, Prentice HA, Winston BA, Kroger EW. Aspirin vs anticoagulants: cohort of 107,000 arthroplasty patients. J Arthroplasty [Internet]. 2023;38(8):1602-1612.e1. Disponible en: http://dx.doi.org/10.1016/j.arth.2023.02.021
13. Reddy GB, Ovadia JE, Yakkanti RR, et al. Morbidity with PE after joint arthroplasty: matched analysis. J Arthroplasty [Internet]. 2022;37(5):948–52. Disponible en: http://dx.doi.org/10.1016/j.arth.2022.01.086
14. Diep R, Garcia D. Does aspirin prevent venous thromboembolism? Hematology Am Soc Hematol Educ Program [Internet]. 2020;2020(1):634–41. Disponible en: http://dx.doi.org/10.1182/hematology.2020000150
15. Pulmonary Embolism Prevention (PEP) trial. Low-dose aspirin for PE and DVT. Lancet. 2000;355(9212):1295–302.
16. Falck-Ytter Y, Francis CW, et al. Antithrombotic guidelines, 9th ed. Chest [Internet]. 2012;141(2 Suppl):e278S-e325S. Disponible en: http://dx.doi.org/10.1378/chest.11-2404
17. Anderson DR, Morgano GP, et al. ASH 2019 guidelines on VTE prevention. Blood Adv [Internet]. 2019;3(23):3898–944. Disponible en: http://dx.doi.org/10.1182/bloodadvances.2019000975
18. Gee E. VTE NICE guideline implementation: UK response. Br J Haematol [Internet]. 2019;186(5):792–3. Disponible en: http://dx.doi.org/10.1111/bjh.16010
19. CRISTAL Study Group. Aspirin vs enoxaparin: CRISTAL trial. JAMA [Internet]. 2022 [citado 12 oct 2024];328(8):719. Disponible en: https://jamanetwork.com/journals/jama/fullarticle/2795528
20. Parvizi J, DeMik DE, et al. LMWH vs aspirin for VTE: Is it better? J Arthroplasty [Internet]. 2023;38(1):1–2. Disponible en: https://linkinghub.elsevier.com/retrieve/pii/S0883540322008610
21. Chan NC, Bhandari M. Thromboprophylaxis after arthroplasty. JAMA [Internet]. 2022 [citado 12 oct 2024];328(8):712. Disponible en: https://jamanetwork.com/journals/jama/article-abstract/2795552
22. Richardson SS, et al. Pharmacologic prophylaxis after TKA. Knee [Internet]. 2019;26(2):451–8. Disponible en: https://linkinghub.elsevier.com/retrieve/pii/S096801601830704X
23. Hu B, et al. Rivaroxaban vs aspirin after arthroplasty or hip fracture: meta-analysis. J Orthop Surg Res [Internet]. 2021;16(1). Disponible en: http://dx.doi.org/10.1186/s13018-021-02274-z
24. Yhim HY, et al. VTE prophylaxis impact after arthroplasty in Korea. PLoS One [Internet]. 2017;12(5):e0178214. Disponible en: http://dx.doi.org/10.1371/journal.pone.0178214
25. Agaba P, et al. VTE complications after THA by drug. J Orthop [Internet]. 2017;14(4):537–43. Disponible en: http://dx.doi.org/10.1016/j.jor.2017.08.002
26. Pellegrini VD Jr, et al. Selection bias in aspirin research. J Bone Joint Surg Am [Internet]. 2020;102(7):631–3. Disponible en: http://dx.doi.org/10.2106/JBJS.19.01135
27. Lindquist DE, et al. Bleeding comparison in arthroplasty patients. Clin Appl Thromb Hemost [Internet]. 2018;24(8):1315–21. Disponible en: http://dx.doi.org/10.1177/1076029618772337
28. Shafiei SH, et al. Low vs high-dose aspirin after TJA: cohort study. Ann Med Surg (Lond) [Internet]. 2023;85(5):1461–7. Disponible en: http://dx.doi.org/10.1097/MS9.0000000000000366
29. Merkow DB, et al. Low-dose aspirin prevents VTE in TKA. J Orthop [Internet]. 2021;24:26–8. Disponible en: http://dx.doi.org/10.1016/j.jor.2021.02.005
30. Azboy I, et al. Low-dose aspirin for VTE in arthroplasty: review. J Arthroplasty [Internet]. 2019;35(3):886–92. Disponible en: http://dx.doi.org/10.1016/j.arth.2019.09.043
31. Mula V, et al. VTE after arthroplasty and hip fractures. BMC Musculoskelet Disord [Internet]. 2020;21(1):95. Disponible en: http://dx.doi.org/10.1186/s12891-020-3100-47
Published
Issue
Section
License
Copyright (c) 2026 Florencia Agustina Rosignoli , Fernando Lipovestky (Author)
This work is licensed under a Creative Commons Attribution 4.0 International License.
The article is distributed under the Creative Commons Attribution 4.0 License. Unless otherwise stated, associated published material is distributed under the same licence.
